This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-20. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
=== Che–Cl === Zhijian James Chen (b. 1966). Chinese-American biochemist at the University of Texas Southwestern Medical Center, known discovering mechanisms by which nucleic acids trigger innate and autoimmune responses from the interior of a cell. Member Natl. Acad. Sci. USA. Albert Chibnall FRS (1894–1988), British biochemist known for his work on the nitrogen metabolism of plants. Ruth Chiquet-Ehrismann (1954–2015), Swiss biochemist and cell biologist working on interactions in the extracellular matrix. Cyrus Chothia FRS (1942–2019). British biochemist at Cambridge known for work on protein structure. Gilbert Chu (b. 1946). American biochemist at Stanford, known for investigating how cells react to DNA damage from radiation. George M. Church (b. 1954). American geneticist at Harvard and MIT, known for pioneering personal genomics and synthetic biology. Member Natl. Acad. Sci. USA. Aaron Ciechanover (b. 1947). Israeli biochemist at the Technion, Haifa, known for work on protein turnover. Nobel Prize for Chemistry in 2004. Foreign associate Natl. Acad. Sci. USA. Vintilă Ciocâlteu (1890–1947) Roumanian physician, biochemist, researcher, professor, and author. Hans Thacher Clarke (1887–1972), British-born American biochemist at Columbia University, known for the Eschweiler–Clarke reaction. Member Natl. Acad. Sci. USA. Jane Clarke (b. 1950). Biochemist at Cambridge known for work on folding and assembly of proteins. Steven Clarke (b. 1949). American biochemist at UCLA, known for work on molecular damage and molecular repair mechanisms. Roy Elwood Clausen (1891–1956).
One barn is 10−28 square metres, about the cross-sectional area of a uranium nucleus. The name probably derives from early neutron-deflection experiments, when the uranium nucleus was described, and the phrases "big as a barn" and "hit a barn door" were used. Barn are typically used for cross sections in nuclear and particle physics. Additional units include the microbarn (or "outhouse") and the yoctobarn (or "shed").
== Applications == PFOA has widespread applications. In 1976, PFOA was reported as a water and oil repellent "in fabrics and leather and in the production of floor waxes and waxed papers"; however, it is believed that paper is no longer treated with perfluorinated compounds, but with fluorotelomers with less than 0.1% PFOA. The compound is also used in "insulators for electric wires, planar etching of fused silica", fire fighting foam, and outdoor clothing. As a protonated species, the acid form of PFOA was the most widely used perfluorocarboxylic acid used as a reactive intermediate in the production of fluoroacrylic esters.
Sources: en.wikipedia.org
=== Cancer === Water-soluble polymer shells are being created to deliver a protein, apoptin, into cancer cells. The protein goes into the nucleus of the cancer cells while leaving healthy cells alone, unlike other conventional therapies as gene therapies and chemotherapy. The capsules are 100 nm in size. Active targeting of cancer cells is also being researched. Through active targeting, the nanocapsules form ligands that bind to malignant cells for cell delivery. This method is especially beneficial for those drugs that are not as permeable through the cell membrane, and where tissues are diseased, the nanoparticles are able to bond easier with the malignant cells.
== Contraindications == Labetalol is contraindicated in people with overt cardiac failure, greater-than-first-degree heart block, severe bradycardia, cardiogenic shock, severe hypotension, anyone with a history of obstructive airway disease including asthma, and those with hypersensitivity to the drug.
Upon image analysis, the subcellular localization of the protein has been classified into one or more of 49 different organelles and subcellular structures. In addition, the resource includes an annotation of genes that display single-cell variation in protein expression levels and/or subcellular distribution, as well as an extended analysis of cell cycle dependency of such variations. The Cell Line resource contains information on genome-wide RNA expression profiles of human protein-coding genes in 1206 human cell lines, including 1132 cancer cell lines. The transcriptomics analysis includes classification based on specificity analysis across 28 cancer types, distribution and expression cluster analysis across all cell lines and for selected cancer types also analysis of similarity of the cell lines to their corresponding cancer type. The Structure resource contains information about the predicted three-dimensional structure of 19904 human proteins and their related isoforms. Interactive 3D protein structures based on predictions generated using the AlphaFold source code are shown with the possibility to highlight selected regions and positions in the structure. The Protein Browser tool displays a variety of features for the different isoforms and can be used to select splice variants and highlight protein related features such as known antigen sequences, transmembrane regions and InterPro domains directly on the structures.
adduct A distinct chemical species that is the sole product of an addition reaction between two other distinct reactant species, in which all of the atoms comprising the reactants are retained in the single product. Changes in connectivity may occur, but there is no loss of any of the original atoms and no gain of atoms that are not present in the reactant molecules. Stoichiometries other than 1:1 are also possible, e.g. a bis-adduct (2:1).
Sources: en.wikipedia.org
=== Vertebrates === In birds, the trachea runs from the pharynx to the syrinx, from which the primary bronchi diverge. Swans have an unusually elongated trachea, part of which is coiled beneath the sternum; this may act as a resonator to amplify sound. In some birds, the tracheal rings are complete, and may even be ossified. In amphibians, the trachea is normally extremely short, and leads directly into the lungs, without clear primary bronchi. A longer trachea is, however, found in some long-necked salamanders, and in caecilians. While there are irregular cartilagenous nodules on the amphibian trachea, these do not form the rings found in amniotes. The only vertebrates to have lungs, but no trachea, are the lungfish and the Polypterus, in which the lungs arise directly from the pharynx.
A very important modification of eukaryotic pre-mRNA is RNA splicing. The majority of eukaryotic pre-mRNAs consist of alternating segments called exons and introns. During the process of splicing, an RNA-protein catalytical complex known as spliceosome catalyzes two transesterification reactions, which remove an intron and release it in form of lariat structure, and then splice neighbouring exons together. In certain cases, some introns or exons can be either removed or retained in mature mRNA. This so-called alternative splicing creates series of different transcripts originating from a single gene. Because these transcripts can be potentially translated into different proteins, splicing extends the complexity of eukaryotic gene expression and the size of a species proteome. Extensive RNA processing may be an evolutionary advantage made possible by the nucleus of eukaryotes. In prokaryotes, transcription and translation happen together, whilst in eukaryotes, the nuclear membrane separates the two processes, giving time for RNA processing to occur.
Trump, an anonymous jury found Trump civilly liable for sexual abuse and defamation, and ordered him to pay Carroll $5 million in damages. In a related case brought by Carroll against Trump, a jury awarded Carroll $83.3 million. As of April 2025, appeals were ongoing in both cases. In September 2023, Trump was found civilly liable for financial fraud in New York v. Trump. In February 2024, he was ordered to pay a $354.8 million fine, together with approximately $100 million in interest. As of January 29, 2025, an appeal was ongoing. Trump made efforts to delay his trials until after the 2024 election. On July 1, 2024, the Supreme Court delivered a 6–3 decision in Trump v. United States, ruling that Trump had absolute immunity for acts he committed as president within his core constitutional purview, at least presumptive immunity for official acts within the outer perimeter of his official responsibility, and no immunity for unofficial acts.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.